Cederqvist Katariina, Haglund Caj, Heikkilä Päivi, Sorsa Timo, Tervahartiala Taina, Stenman Ulf-Håkan, Andersson Sture
Hospital for Children and Adolescents, Helsinki University Central Hospital, Helsinki, Finland.
Pediatrics. 2003 Sep;112(3 Pt 1):570-7. doi: 10.1542/peds.112.3.570.
In the preterm infant, lung injury can lead to irreversible tissue destruction and abnormal lung development. We examined whether pulmonary trypsin, a potent matrix-degrading serine proteinase and proteinase-cascade activator, is associated with the development of bronchopulmonary dysplasia (BPD) in preterm infants.
Samples of tracheal aspirate fluid were collected from 32 intubated preterm infants during their first 2 postnatal weeks. The presence and molecular forms of trypsin in tracheal aspirate fluid samples were analyzed by zymography and Western blotting. The concentrations of trypsinogen-1 and -2 and tumor-associated trypsin inhibitor were measured by immunofluorometry. For examining the expression of trypsin-2 in lung tissue, immunohistochemistry was performed on autopsy specimens of fetuses, of preterm infants who died from respiratory distress syndrome or BPD, and of term infants without lung injury.
In infants who subsequently developed BPD (n = 18), we detected significantly higher concentrations of trypsinogen-2 during postnatal days 5 to 10 compared with those who survived without it. There was no difference in trypsinogen-1 concentrations. Tumor-associated trypsin inhibitor concentrations were significantly lower in infants who needed mechanical ventilation for >1 week. Immunohistochemistry demonstrated that trypsin-2 was predominantly expressed in bronchial and bronchiolar epithelium. In 2 preterm infants who died from prolonged respiratory distress syndrome, trypsin-2 was also expressed in vascular endothelium.
The levels of trypsinogen-2 are higher during postnatal days 5 to 10 in infants who subsequently develop BPD. The results suggest that high levels of pulmonary trypsin-2 may be associated with the development of BPD. This raises the possibility that therapy with exogenous proteinase inhibitors might prevent the development of BPD in preterm infants with respiratory distress.
在早产儿中,肺损伤可导致不可逆的组织破坏和肺发育异常。我们研究了肺胰蛋白酶(一种强效的基质降解丝氨酸蛋白酶和蛋白酶级联激活剂)是否与早产儿支气管肺发育不良(BPD)的发生有关。
在出生后的前2周内,从32例插管的早产儿中收集气管吸出液样本。通过酶谱分析和蛋白质印迹法分析气管吸出液样本中胰蛋白酶的存在和分子形式。通过免疫荧光法测定胰蛋白酶原-1和-2以及肿瘤相关胰蛋白酶抑制剂的浓度。为了检测肺组织中胰蛋白酶-2的表达,对胎儿、死于呼吸窘迫综合征或BPD的早产儿以及无肺损伤的足月儿的尸检标本进行免疫组织化学检测。
在随后发生BPD的婴儿(n = 18)中,我们检测到出生后第5至10天胰蛋白酶原-2的浓度明显高于未发生BPD而存活的婴儿。胰蛋白酶原-1浓度没有差异。需要机械通气超过1周的婴儿中,肿瘤相关胰蛋白酶抑制剂浓度明显较低。免疫组织化学显示胰蛋白酶-2主要表达于支气管和细支气管上皮。在2例死于长期呼吸窘迫综合征的早产儿中,胰蛋白酶-2也表达于血管内皮。
随后发生BPD的婴儿在出生后第5至10天胰蛋白酶原-2水平较高。结果表明,高水平的肺胰蛋白酶-2可能与BPD的发生有关。这增加了使用外源性蛋白酶抑制剂治疗可能预防呼吸窘迫早产儿发生BPD的可能性。